English | Español

Johnson & Johnson
Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission | Dec 20, 2019

JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Press release submission | Jun 14, 2019

JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis

Trending
Patient Daily | Jul 25, 2025

Healthcare CEO on 340B reform: ‘It’s the abuse by very large, very profitable, tax-exempt institutions that I think needs to change'
Patient Daily | Jul 24, 2025

Long School of Medicine is largest physician trainer in South Texas
Patient Daily | Jul 25, 2025

Balloon sinuplasty marks 20 years since FDA approval
+ Pharmaceuticals
Patient Daily | Jul 22, 2025

Deputy VP of Public Affairs of PhRMA: 'It's time for Congress to fix the 340B Drug Pricing Program'